A1 Refereed original research article in a scientific journal
Favorable outcome of cancer patients undergoing transcatheter aortic valve replacement
Authors: Fausto Biancari, Sebastian Dahlbacka, Tatu Juvonen, Marko P.O. Virtanen, Pasi Maaranen, Jussi Jaakkola, Teemu Laakso, Matti Niemelä, Tuomas Tauriainen, Antti Vento, Annastiina Husso, Mikko Savontaus, Mika Laine, Timo Mäkikallio, Peter Raivio, Markku Eskola, Stefano Rosato, Vesa Anttila, Juhani Airaksinen, Antti Valtola
Publisher: Elsevier/North-Holland
Publication year: 2020
Journal: International Journal of Cardiology
Journal name in source: International journal of cardiology
Journal acronym: Int J Cardiol
Volume: 315
Number of pages: 4
ISSN: 0167-5273
eISSN: 1874-1754
DOI: https://doi.org/10.1016/j.ijcard.2020.03.038
Self-archived copy’s web address: https://helda.helsinki.fi/bitstream/10138/328168/1/1_s2.0_S0167527319355469_main.pdf
The aim of this study was to assess the outcome of transcatheter aortic valve replacement (TAVR) in patients with cancer.In this cohort, 417 patients (19.6%) had history of cancer and 113 (5.3%) had an active malignancy at the time of TAVR. Patients with any malignancy had similar late mortality than patients without any malignancy (at 7 years, 65.1% vs. 59.3%, adjusted HR 1.105, 95%CI 0.892-1.369). At 7 years, cancer-related mortality was 22.5% among patients with preoperative cancer, and 11.0% in those without preoperative cancer (p < 0.0001). Among cancer patients, 18 died of the same disease (at 7 years, mortality 12.5%). Active malignancy was not associated with increased risk of all-cause mortality (adjusted HR 1.100, 95%CI 0.757-1.599). However, patients with blood malignancies had a significantly increased risk of mortality (at 4-year, 53.5% vs. 35.4%, adjusted HR 2.029, 95%CI 1.328-3.098).This is a retrospective study from the nationwide FinnValve registry on 2130 consecutive patients who underwent TAVR for severe AS from January 2008 to October 2017.ClinicalTrials.gov Identifier: NCT03385915; https://clinicaltrials.gov/ct2/show/NCT03385915.This analysis showed that, when properly selected by the heart team and oncologists, most cancer patients undergoing TAVR can achieve a good survival and eventually die of other diseases. Blood malignancies seem to carry a poor prognosis in these patients.
